CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Elena Fountzilas et al.|Journal of Clinical Oncology|2024Cited by 57
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry studyLauren Brown, Benjamin Y. Kong, Victor Khou et al.|Frontiers in Oncology|2024Cited by 6
Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)Silvia Novello, Giorgio V. Scagliotti, Anna K. Nowak et al.|Annals of Oncology|2017Cited by 0